Israeli co Nectin Therapeutics raises $25m
Israeli biotechnology company Nectin Therapeutics has announced that it has completed a $25 million Series A financing round led by IBF and Peregrine Ventures, with participation from aMoon Fund and other existing investors.
Jerusalem-based Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The